Literature DB >> 16917685

Treatment of alcohol withdrawal syndrome with a combination of tiapride/carbamazepine: results of a pooled analysis in 540 patients.

Michael Soyka1, Peggy Schmidt, Michael Franz, Thomas Barth, Michael de Groot, Thorsten Kienast, Thomas Reinert, Christoph Richter, Greif Sander.   

Abstract

This was a retrospective study to examine the efficacy, practicability and medical safety of a combination of tiapride and unretarded (fast acting formula) carbamazepine in the treatment of alcohol withdrawal syndrome. In five hospitals using this combination for treatment of alcohol withdrawal, 540 patients who had been treated with this combination were identified. An intensive evaluation of patients files and charts was performed. Details of alcohol history and comorbid disorders were extracted from patient files. Severity of alcohol withdrawal had been assessed using the CIWA-A-Score. Gender differences and differences between patients in their first and at least second withdrawal were computed by means of variance analyses (GLM). At baseline (day 1) mean dosage given was 796 for tiapride and 543 mg for carbamazepine. A pooled analysis of the results showed that, in general, medication was well tolerated. Withdrawal symptomatology as indicated by CIWA-A scores clearly decreased over time. Although a significant number of patients had a history of alcohol withdrawal delirium (103) and epileptic seizures (151), few patients suffered from them during treatment (8 and 5, respectively). Only 24 (4.4%) patients dropped out because of lack of efficacy or change of medication, 15 (2.8%) because of side effects. No case of malignant neuroleptic syndrome was recorded. Data analysis showed gender differences and differences between patients in their first and at least second withdrawal for side effects, complications, and in some CIWA-A-scores. In general, severe complications of withdrawal syndrome were more frequent in men compared to women and in patients with repeated inpatient treatment. In line with previous research, the results from this study give further evidence that a combination of the anticonvulsant carbamazepine and tiapride is an effective and safe treatment for alcohol withdrawal treatment.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16917685     DOI: 10.1007/s00406-006-0644-8

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Clin Neurosci        ISSN: 0940-1334            Impact factor:   5.270


  34 in total

Review 1.  An overview of the development of medications including novel anticonvulsants for the treatment of alcohol dependence.

Authors:  Bankole A Johnson
Journal:  Expert Opin Pharmacother       Date:  2004-09       Impact factor: 3.889

2.  Double-blind controlled trial comparing carbamazepine to oxazepam treatment of alcohol withdrawal.

Authors:  R Malcolm; J C Ballenger; E T Sturgis; R Anton
Journal:  Am J Psychiatry       Date:  1989-05       Impact factor: 18.112

3.  A double-blind, placebo-controlled pilot study of carbamazepine for the treatment of alcohol dependence.

Authors:  T I Mueller; R L Stout; S Rudden; R A Brown; A Gordon; D A Solomon; P R Recupero
Journal:  Alcohol Clin Exp Res       Date:  1997-02       Impact factor: 3.455

4.  Assessment of alcohol withdrawal: the revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar).

Authors:  J T Sullivan; K Sykora; J Schneiderman; C A Naranjo; E M Sellers
Journal:  Br J Addict       Date:  1989-11

5.  The preclinical pharmacologic profile of tiapride.

Authors:  B Scatton; C Cohen; G Perrault; A Oblin; Y Claustre; H Schoemaker; D J Sanger; L Rouquier; R Porsolt
Journal:  Eur Psychiatry       Date:  2001-01       Impact factor: 5.361

6.  Clinical management of agitation in the elderly with tiapride.

Authors:  P H Robert; H Allain
Journal:  Eur Psychiatry       Date:  2001-01       Impact factor: 5.361

7.  Management of alcohol withdrawal delirium. An evidence-based practice guideline.

Authors:  Michael F Mayo-Smith; Lee H Beecher; Timothy L Fischer; David A Gorelick; Jeanette L Guillaume; Arnold Hill; Gail Jara; Chris Kasser; John Melbourne
Journal:  Arch Intern Med       Date:  2004-07-12

Review 8.  [Carbamazepine in treatment of alcohol withdrawal syndrome--an overview of current research].

Authors:  J Thome; G A Wiesbeck; G H Vince
Journal:  Fortschr Neurol Psychiatr       Date:  1994-04       Impact factor: 0.752

9.  Treatment of alcohol withdrawal: chlormethiazole vs. carbamazepine and the effect on memory performance--a pilot study.

Authors:  J Seifert; E Peters; K Jahn; C Metzner; M Ohlmeier; B te Wildt; H M Emrich; U Schneider
Journal:  Addict Biol       Date:  2004-03       Impact factor: 4.280

10.  Tiapride and chlordiazepoxide in acute alcohol withdrawal. A controlled clinical trial.

Authors:  U Lepola; S Kokko; J Nuutila; A Gordin
Journal:  Int J Clin Pharmacol Res       Date:  1984
View more
  3 in total

Review 1.  Are Alcohol Anti-relapsing and Alcohol Withdrawal Drugs Useful in Cannabinoid Users?

Authors:  Patrycja Kleczkowska; Irena Smaga; Małgorzata Filip; Magdalena Bujalska-Zadrozny
Journal:  Neurotox Res       Date:  2016-08-02       Impact factor: 3.911

Review 2.  Sex differences in neuroadaptation to alcohol and withdrawal neurotoxicity.

Authors:  Lynda Sharrett-Field; Tracy R Butler; Anna R Reynolds; Jennifer N Berry; Mark A Prendergast
Journal:  Pflugers Arch       Date:  2013-04-05       Impact factor: 3.657

3.  Mitochondrial ATP transporter depletion protects mice against liver steatosis and insulin resistance.

Authors:  Joonseok Cho; Yujian Zhang; Shi-Young Park; Anna-Maria Joseph; Chul Han; Hyo-Jin Park; Srilaxmi Kalavalapalli; Sung-Kook Chun; Drake Morgan; Jae-Sung Kim; Shinichi Someya; Clayton E Mathews; Young Jae Lee; Stephanie E Wohlgemuth; Nishanth E Sunny; Hui-Young Lee; Cheol Soo Choi; Takayuki Shiratsuchi; S Paul Oh; Naohiro Terada
Journal:  Nat Commun       Date:  2017-02-16       Impact factor: 14.919

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.